Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Free Cash Flow: 2013-2024

Historic Free Cash Flow for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to -$149.0 million.

  • Seres Therapeutics' Free Cash Flow rose 106.31% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year increase of 85.25%. This contributed to the annual value of -$149.0 million for FY2024, which is 18.88% down from last year.
  • Per Seres Therapeutics' latest filing, its Free Cash Flow stood at -$149.0 million for FY2024, which was down 18.88% from -$125.3 million recorded in FY2023.
  • Seres Therapeutics' Free Cash Flow's 5-year high stood at -$2.9 million during FY2021, with a 5-year trough of -$238.6 million in FY2022.
  • Its 3-year average for Free Cash Flow is -$171.0 million, with a median of -$149.0 million in 2024.
  • In the last 5 years, Seres Therapeutics' Free Cash Flow surged by 96.94% in 2021 and then plummeted by 8,191.77% in 2022.
  • Over the past 5 years, Seres Therapeutics' Free Cash Flow (Yearly) stood at -$94.2 million in 2020, then surged by 96.94% to -$2.9 million in 2021, then slumped by 8,191.77% to -$238.6 million in 2022, then skyrocketed by 47.48% to -$125.3 million in 2023, then dropped by 18.88% to -$149.0 million in 2024.